医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NanoLuc™ Luciferase Technology Named to The Scientist Top 10 Innovations for 2012

2012年12月18日 AM12:25
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

Promega NanoLuc Luciferase Technology named to The Scientist Top 10 Innovations for 2012 (Photo: Business Wire)Promega NanoLuc Luciferase Technology named to The Scientist Top 10 Innovations for 2012 (Photo: Business Wire)

View and Share Photo

Close Window


MADISON, Wis.

Promega Corporation is pleased to announce that The Scientist has named NanoLuc™ Luciferase Technology to its 2012 Top 10 Innovations. NanoLuc is a novel luciferase that is smaller, brighter, and more versatile than any current bioluminescent enzyme.

Promega NanoLuc Luciferase Technology named to The Scientist Top 10 Innovations for 2012 (Photo: Bus ...

Promega NanoLuc Luciferase Technology named to The Scientist Top 10 Innovations for 2012 (Photo: Business Wire)

NanoLuc was first commercialized in May 2012 with 12 plasmid constructs and the Nano-Glo™ Reagent for reporter applications. NanoLuc is an enabling platform technology upon which Promega is developing additional assay solutions for difficult biology. The technology has already demonstrated its value to viral delivery and protein fusion applications. The versatility of NanoLuc is being further pursued by the Advanced Technologies Group and Research & Development teams at Promega.

In addition to in-house development, Promega is collaborating with complementary next-gen assay technologies to better serve basic and pharmaceutical research. Key collaborations using NanoLuc include coupling with 3D cell culture models (InSphero) and combining with genetically-defined reporter cell lines generated using the proprietary GENESIS™ gene editing technology (Horizon Discovery Ltd).

To learn more about this enabling technology, request a sample or view a webinar, please see www.promega.com/nanoluc.

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20121217005291/en/

CONTACT

Promega Corporation
Penny Patterson
Sr. Director,
Communications
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates